Literature DB >> 22087868

Population pharmacokinetic/pharmacodynamic analyses as the basis for dosing of therapeutic monoclonal antibodies.

Bernd Meibohm1.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 22087868     DOI: 10.2165/11597950-000000000-00000

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  5 in total

Review 1.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

2.  Concepts and challenges in quantitative pharmacology and model-based drug development.

Authors:  Liping Zhang; Marc Pfister; Bernd Meibohm
Journal:  AAPS J       Date:  2008-11-12       Impact factor: 4.009

3.  Approximations of the target-mediated drug disposition model and identifiability of model parameters.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky; Tarundeep Kakkar; Peiming Ma
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-11-13       Impact factor: 2.745

4.  Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis.

Authors:  Liviawati Sutjandra; Rachelle D Rodriguez; Sameer Doshi; Mark Ma; Mark C Peterson; Graham R Jang; Andrew T Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2011-12-01       Impact factor: 6.447

5.  Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.

Authors:  Diane D Wang; Shuzhong Zhang; Hong Zhao; Angela Y Men; Kourosh Parivar
Journal:  J Clin Pharmacol       Date:  2009-07-20       Impact factor: 3.126

  5 in total
  1 in total

1.  Target-mediated disposition model describing the dynamics of IL12 and IFNγ after administration of a mifepristone-inducible adenoviral vector for IL-12 expression in mice.

Authors:  Zinnia Patricia Parra-Guillen; Alvaro Janda; Pilar Alzuguren; Pedro Berraondo; Ruben Hernandez-Alcoceba; Iñaki F Troconiz
Journal:  AAPS J       Date:  2012-11-08       Impact factor: 4.009

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.